
Search documents
新华医疗(600587):2025年中报点评:制药装备稳健增长,逐步剥离低毛利业务
Huachuang Securities· 2025-09-16 01:14
证 券 研 究 报 告 新华医疗(600587)2025 年中报点评 推荐(维持) 制药装备稳健增长,逐步剥离低毛利业务 目标价:20 元 事项: ❖ 公司发布 25 年中报,25H1 营收 47.90 亿元(-7.64%),归母净利润 3.86 亿元 (-20.35%),扣非归母净利润 3.33 亿元(-29.75%)。单 25Q2,营收 24.83 亿 元(-6.59%),归母净利润 2.25 亿元(-17.55%),扣非归母净利润 1.75 亿元(- 33.87%)。 评论: [ReportFinancialIndex] 主要财务指标 公司研究 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 10,021 | 10,675 | 11,776 | 12,968 | | 同比增速(%) | 0.1% | 6.5% | 10.3% | 10.1% | | 归母净利润(百万) | 692 | 798 | 928 | 1,026 | | 同比增速(%) | 5.8% | 15.4% | 16.3% ...
大族激光(002008):深度研究报告:AI端侧、AIPCB、独角兽资产三箭齐发,平台型科技龙头开启新一轮周期
Huachuang Securities· 2025-09-15 15:05
Investment Rating - The report assigns a "Strong Buy" rating to the company, with a target price of 65.13 CNY based on a projected 30x PE for 2026 [3][11]. Core Insights - The company is positioned to benefit from a new growth cycle driven by AI edge computing and AI PCB expansion, following a historical pattern of stock price and operational cycles [9][37]. - The company has established itself as a leading global provider of intelligent manufacturing equipment solutions, with a diversified product range across various sectors including consumer electronics, new energy, and semiconductors [15][18]. Summary by Sections Company Overview - The company has evolved over 30 years into a platform technology leader, with a comprehensive product portfolio that includes equipment for information technology, new energy, semiconductor, and general laser processing [15][18]. - The management team possesses extensive industry experience, contributing to stable operational performance [25][26]. Consumer Electronics - Major clients are initiating a new innovation cycle, with AI hardware upgrades driving increased equipment demand [40]. - The company is actively expanding its product offerings in 3D printing and other new technologies to meet evolving market needs [40][48]. AI PCB - The AI sector is expected to trigger the largest expansion wave in PCB manufacturing, with a surge in equipment demand driven by high-density and high-performance requirements [9][11]. - The company holds the leading market share in PCB equipment, particularly in drilling and imaging technologies, positioning it well to capitalize on industry growth [9][11]. Financial Projections - Revenue forecasts indicate a growth trajectory with total revenue expected to reach 29.9 billion CNY by 2027, reflecting a compound annual growth rate of 21.5% [3][11]. - Net profit is projected to rebound significantly, with estimates of 3.33 billion CNY by 2027, following a dip in 2025 [3][11]. Investment Thesis - The combination of AI edge computing and AI PCB advancements is anticipated to drive a new growth cycle for the company, supported by historical performance patterns [9][37]. - The company has successfully incubated numerous subsidiary companies, enhancing its competitive edge across various technology sectors [10][11].
传媒行业周观察(20250908-20250912):互联网厂商AI布局加速,看好游戏板块Q3高景气,湖南民办高教转营有切实进展
Huachuang Securities· 2025-09-15 12:44
证 券 研 究 报 告 传媒行业周观察(20250908-20250912) 互联网厂商 AI 布局加速,看好游戏板块 Q3 推荐(维持) 高景气,湖南民办高教转营有切实进展 【市场观点】 【投资建议】 行业研究 证券分析师:赵海楠 邮箱:zhaohainan@hcyjs.com 执业编号:S0360524070016 行业基本数据 | | | 占比% | | --- | --- | --- | | 股票家数(只) | 140 | 0.02 | | 总市值(亿元) | 19,595.28 | 1.67 | | 流通市值(亿元) | 17,850.96 | 1.89 | 相对指数表现 | % | 1M | 6M | 12M | | --- | --- | --- | --- | | 绝对表现 | 11.2% | 19.1% | 87.0% | | 相对表现 | 2.0% | 4.0% | 44.5% | 传媒 2025 年 09 月 15 日 华创证券研究所 证券分析师:刘欣 邮箱:liuxin3@hcyjs.com 执业编号:S0360521010001 0% 31% 61% 92% 24/09 24/11 ...
2025Q2企业年金数据点评:企业年金规模提速增长至3.84万亿
Huachuang Securities· 2025-09-15 11:15
行业研究 保险Ⅲ 2025 年 09 月 15 日 证 券 研 究 报 告 2025Q2 企业年金数据点评 推荐(维持) 企业年金规模提速增长至 3.84 万亿 华创证券研究所 | 证券分析师:陈海椰 | 证券分析师:徐康 | | --- | --- | | 邮箱:chenhaiye@hcyjs.com | 电话:021-20572556 | | 执业编号:S0360525070004 | 邮箱:xukang@hcyjs.com | | | 执业编号:S0360518060005 | 事项: 9 月 9 日,人社部发布《2025 年二季度全国企业年金基金业务数据摘要》。截至 2025Q2,企业年金积累基金规模达到 3.84 万亿,近三年累计收益率为 6.27%。 评论: 企业年金规模较 Q1 提速增长,建立企业、参与职工环比增速放缓。截至 2025Q2,企业 年金积累基金规模达到 3.84 万亿,环比 2025Q1 增长 3.11%,增幅环比扩大 0.73pct。从 覆盖面来看,建立企业数量达到 17.24 万个,环比 2025Q1 增加 2.44%,增幅环比收窄 3.19pct;参加职工环比+0.42%至 ...
美团-W(03690):25Q2业绩点评:短期即时零售竞争压制利润,观察后续竞争节奏和新业务进展
Huachuang Securities· 2025-09-15 10:44
Investment Rating - The report maintains a "Recommendation" rating for Meituan-W (03690.HK) [1] Core Views - The company reported Q2 2025 earnings with revenue of 91.84 billion yuan, a year-on-year increase of 11.7% and a quarter-on-quarter increase of 6.1%. However, the gross margin decreased to 33.1% from 41.2% in the same period last year, and the adjusted net profit was 1.49 billion yuan, down 89.0% year-on-year [1][4] - The intense competition in instant retail is suppressing profits, and the recovery of profitability in the short term needs to be observed in terms of competitive dynamics and new business developments [1][4] - The core local business revenue reached 65.35 billion yuan, up 7.7% year-on-year, while new business revenue grew by 22.8% to 26.49 billion yuan, driven by grocery retail and overseas expansion [1][4] Financial Summary - Total revenue projections for 2024A, 2025E, 2026E, and 2027E are 337.59 billion yuan, 373.99 billion yuan, 427.68 billion yuan, and 489.47 billion yuan respectively, with year-on-year growth rates of 22.0%, 10.8%, 14.4%, and 14.4% [3] - Adjusted net profit forecasts for the same years are 43.77 billion yuan, -10.21 billion yuan, 15.78 billion yuan, and 38.55 billion yuan, with year-on-year growth rates of 88.2%, -123.3%, 254.6%, and 144.3% [3] - The target price for the stock is set at 127.93 HKD, with the current price at 96.55 HKD, indicating a potential upside [4]
特朗普“接管”美联储?
Huachuang Securities· 2025-09-15 10:44
宏观研究 证 券 研 究 报 告 【宏观快评】 特朗普"接管"美联储? 主要观点 ❖ 美联储的结构 美联储是联邦政府独立机构(行政分支),受美国国会监督,但独立决策。从 概念上讲,美联储不是一个单一的中央银行,而是一个中央银行"系统",其 有三大特征:一个中央管理委员会;由 12 家储备银行组成的分散式运营架构; 兼具公共和私人特征。从结构上来看,美联储系统有三个核心的实体:美联储 理事会(美联储管理机构,对应特征一)、12 家储备银行(储备银行是独立注 册的法人机构,储备银行辖区内的商业银行在储备银行中持有股份,对应特征 二和三)、联邦公开市场委员会(货币政策制定机构)。 关于三大实体的构成、任命方式和职能,参见正文。 ❖ 美联储的决策机制:简单多数和绝对多数 1、美联储理事会有 7 个理事(包括美联储主席),一人一票,以简单多数决 策,部分行动需要绝对多数。理事会下设 8 个委员会,由不同理事成员组成, 不同的委员会聚焦于不同领域,但包括新规则发布和规则修改、监管指南、监 管和监督事项、紧急措施、执法行动、银行订单、理事会行动等所有事项的决 定,都需要理事会成员投票来决定,规则是简单多数。在特殊和紧急情况 ...
亿纬锂能(300014):动力大圆柱开始量产出货,储能领域增势较好
Huachuang Securities· 2025-09-15 09:41
证 券 研 究 报 告 亿纬锂能(300014)2025 年中报点评 强推(维持) 动力大圆柱开始量产出货,储能领域增势较好 事项: 评论: [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 48,615 | 65,950 | 82,581 | 108,436 | | 同比增速(%) | -0.3% | 35.7% | 25.2% | 31.3% | | 归母净利润(百万) | 4,076 | 4,573 | 6,433 | 8,152 | | 同比增速(%) | 0.6% | 12.2% | 40.7% | 26.7% | | 每股盈利(元) | 1.99 | 2.24 | 3.14 | 3.98 | | 市盈率(倍) | 37 | 33 | 23 | 19 | | 市净率(倍) | 4.0 | 3.7 | 3.3 | 2.9 | 资料来源:公司公告,华创证券预测 注:股价为 2025 年 9 月 12 日收盘价 公司研究 锂电池 20 ...
安图生物(603658):国内发光业务承压,Q2环比改善
Huachuang Securities· 2025-09-15 09:41
证 券 研 究 报 告 安图生物(603658)2025 年中报点评 推荐(维持) 国内发光业务承压,Q2 环比改善 目标价:51 元 事项: 化学制剂 2025 年 09 月 15 日 当前价:41.13 元 华创证券研究所 证券分析师:郑辰 邮箱:zhengchen@hcyjs.com 执业编号:S0360520110002 ❖ 公司发布 25 年中报。2025 年上半年,公司实现营业收入 20.60 亿元(-6.65%), 归母净利润 5.71 亿元(-7.83%),扣非归母净利润 5.46 亿元(-8.79%)。单 25Q2, 实现营业收入 10.64 亿元(-4.79%),归母净利润 3.01 亿元(+1.97%),扣非归 母净利润 2.89 亿元(+1.58%)。 评论: [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 4,471 | 4,658 | 5,291 | 6,094 | | 同比增速(%) | 0.6% | 4. ...
维力医疗(603309):海外持续高增长,国内业务承压
Huachuang Securities· 2025-09-15 07:41
证 券 研 究 报 告 维力医疗(603309)2025 年中报点评 推荐(维持) 海外持续高增长,国内业务承压 目标价:19 元 事项: ❖ 公司发布 25 年中报,25H1 营收 7.45 亿元(+10.19%),归母净利润 1.21 亿元 (+14.17%),扣非净利润 1.18 亿元(+16.42%)。单 25Q2,营收 3.97 亿元 (+8.16%),归母净利润0.62亿元(+11.39%),扣非净利润 0.61亿元(+12.87%)。 评论: [主要财务指标 ReportFinancialIndex] | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 1,509 | 1,740 | 2,048 | 2,368 | | 同比增速(%) | 8.8% | 15.3% | 17.7% | 15.6% | | 归母净利润(百万) | 219 | 264 | 318 | 388 | | 同比增速(%) | 14.0% | 20.3% | 20.2% | 22.2% | | 每股盈利(元) | ...
海吉亚医疗(06078):业绩短期承压,看好长期稳步修复
Huachuang Securities· 2025-09-15 07:41
证 券 研 究 报 告 海吉亚医疗(06078.HK)2025 年半年报点评 推荐(维持) 业绩短期承压,看好长期稳步修复 目标价:16.44 港元 资料来源:公司公告,华创证券预测 注:股价为 2025 年 9 月 12 日收盘价 公司研究 医药 2025 年 09 月 15 日 | | | ❖ 公司发布 2025 年半年报。报告期内,公司实现营收 19.90 亿元(-16.47%),归 母净利润 2.47 亿元(-35.76%),经调整净利润 2.63 亿元(-34.5%),经调整净 利率 13.2%(-3.6pct);业绩承压。 评论: 华创证券研究所 [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 4,446 | 4,597 | 4,989 | 5,405 | | 同比增速(%) | 9.0% | 3.4% | 8.5% | 8.3% | | 归母净利润(百万) | 598 | 515 | 628 | 718 | | 同比增速( ...